β³ Fetching live dividend data...
Home βΊ Calculator βΊ RVPH Dividend Calculator 2026
Reviva Pharmaceuticals Holdings, Inc. Β· NASDAQ
Price: $0.41 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in RVPH β $500361.85M in 10 years Β· $34,614,517,499.20/month
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentionΒdeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open RVPH position with:
Real after-tax yield depends on where you live and how you hold RVPH.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 488.75% | 485.95% | $48,875 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 415.44% | 412.64% | $41,544 / yr |
| πΊπΈ US Taxable (20%) | 20% | 391.00% | 388.20% | $39,100 / yr |
| π¬π§ UK ISA | 0% | 488.75% | 485.95% | $48,875 / yr |
| π¬π§ UK Taxable | 8.75% | 445.98% | 443.18% | $44,598 / yr |
| π¨π¦ TFSA | 0% | 488.75% | 485.95% | $48,875 / yr |
| π¨π¦ CA Taxable | 25% | 366.56% | 363.76% | $36,656 / yr |
| π¦πΊ Super (pension) | 15% | 415.44% | 412.64% | $41,544 / yr |
| π¦πΊ AU Taxable | 30% | 342.13% | 339.32% | $34,213 / yr |
| π©πͺ DE Taxable | 26.375% | 359.84% | 357.04% | $35,984 / yr |
| π«π· FR Taxable | 30% | 342.13% | 339.32% | $34,213 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
RVPH pays quarterly β 4 times per year. Next ex-div: TBD.
How RVPH compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RVPH sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-03-18 | 40,925 | $1.87 | $76.5K | ||
| A-Award | 2026-03-18 | 109,150 | $1.87 | $204.1K | ||
| A-Award | 2026-03-18 | 40,925 | $1.87 | $76.5K | ||
| A-Award | 2025-12-18 | 8,200 | $0.58 | $4.8K | ||
| A-Award | 2025-12-18 | 8,200 | $0.58 | $4.8K | ||
| A-Award | 2025-12-18 | 8,200 | $0.58 | $4.8K | ||
| A-Award | 2025-12-18 | 8,200 | $0.58 | $4.8K | ||
| A-Award | 2025-02-13 | 194,250 | $1.80 | $349.6K | ||
| A-Award | 2025-02-13 | 519,000 | $1.80 | $934.2K | ||
| A-Award | 2025-02-13 | 181,500 | $1.80 | $326.7K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RVPH dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review β